First rival but no price cut for $20M drug

Novartis has a $20 million drug facing first new brand competition with the October listing of three generic competitors, but there's been no price drop on the PBS.

To see the whole article please log in.

James Quintana Pearce

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here